Episode
AI Designed Drugs Face Their Reckoning: Isomorphic Labs, Insilico's Phase 3, and Medicine's Make or Break Year - July 20, 2026
- Published
- Jul 20, 2026
- Duration seconds
- 818
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/dx-today-no-hype-podcast-news-about-ai-dx-6434212/episodes/ai-designed-drugs-face-their-reckoning-isomorphic-labs-insilico-s-phase-3-and-medicine-s-make-or-break-year-july-20-2026/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dx-today-no-hype-podcast-news-about-ai-dx-6434212/ai-designed-drugs-face-their-reckoning-isomorphic-labs-insilico-s-phase-3-and-medicine-s-make-or-break-year-july-20-2026.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
AI Designed Drugs Face Their Reckoning: Isomorphic Labs, Insilico's Phase 3, and Medicine's Make or Break Year Two milestones just turned AI drug discovery from promise into a real world test. Isomorphic Labs, the Google DeepMind spinoff built on the AlphaFold lineage, is moving its first AI designed molecules into human oncology trials, while Insilico Medicine has pushed rentosertib, an AI discovered treatment for the lung disease idiopathic pulmonary fibrosis, into a pivotal Phase 3 study...